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Introduction
Benign prostatic hyperplasia (BPH) is a progressive age-related pathologic proliferation of prostatic glandular and stromal tissues (Isaacs 1994) . BPH is clinically characterized by urinary frequency, urgency, nocturia, decreased and intermittent force of stream, and sensation of incomplete bladder emptying. There is no completely effective treatment for BPH. Medical therapies include α-adrenergic blockers, 5α-reductase inhibitors (5-ARIs) and their combinations. Although evidence from clinical practice has proven the efficacy of these agents in providing symptomatic benefit, a plethora of side effects is associated with the use of these drugs. Surgery, usually transurethral prostate resection, is currently the most effective intervention for BPH, but it is also associated with a multitude of postoperative systemic complications commonly referred to as the TURP syndrome (Ventura et al. 2011) . Thus, exploration of safer and more economical treatments are clearly needed. D r a f t 6 extract (equivalent to100 mg, 200 mg SDG) was safe and well-tolerated and improved the quality of life of individuals with BPH. Moreover, a high quality randomized controlled trial (RCT) conducted by Zhang et al. (Zhang et al. 2008) showed that comparing with placebo, SDG supplementation (300 mg, 600 mg) significantly decreased the International Prostate Symptom Score (IPSS), improved the Quality of Life score (QOL score), alleviated lower urinary tract symptoms (LUTS). More importantly, the therapeutic efficacy appeared comparable to that of commonly used intervention agents of α-adrenergic blockers and 5-ARIs (Zhang et al. 2008 ). Although evidence from clinical trials has proved the beneficial effects of SDG on BPH alleviation, the underlying mechanisms are unclear.
SDG, a kind of lignans, which are hydroxylated bicyclobenzylbutane diol derivatives.
After consumption, SDG is converted by the intestinal microbiota to mammalian lignan of enterolactone (ENL), the major form in the biological fluids of humans and animals (Borriello et al. 1985) . ENL is a polyphenol compound and its chemical structure is similar with estradiol. Estrogen can modulate cellular physiology by both genomic and non-genomic pathways. Many of its rapid, non-genomic effects have been suggested to be mediated via the activation of a new type membranous estrogen sensitive G-protein coupled receptor (G-protein-coupled estrogen receptor 1, GPER; or formerly known as GPR30 ) (Gencel et al. 2012) . Activation of GPER leads to c-SRC-dependent trans-activation of the epidermal growth factor receptor (EGFR) and consequent stimulation of ERK 1/2 (Filardo et al. 2000) and PI3K/AKT D r a f t 7 pathways (Meyer et al. 2014) . Previously, we demonstrated that ENL suppressed IGF-1 induced proliferation of prostate cancer cells by inhibiting its downstream AKT phosphorylation (Chen et al. 2009 ). As membrane receptors initiate cascades of phosphorylation events (Smith et al. 2016) , we are wondering whether ENL could interact with GPER.
In this study, we showed the inhibitory role of ENL in the growth of BPH both in vitro and in vivo by investigating the effects of ENL on GPER and its downstream ERK1/2 kinase activation cascade that is causally linked to up-regulation of p21, and cell-cycle arrest at the G1 phase.
Materials and methods

Chemicals and reagents
Testosterone propionate (TP) was purchased from Shanghai general pharmaceutical co., LTD (Shanghai, China). SDG was from Biopurify Phytochemicals (Chengdu,
All the molecular structures of G-1 and ENL were screened "in silico". To analyse the potential interaction between GPER and ENL, we build a model of GPER by homology and operate the program on Discovery Studio 4.0 Modeler (Biovia, Inc., San Diego, CA). Bovine rhodopsin (PDB code 1U19) sharing 40% amino acid sequence with GPER, was choose as the template to build GPER model (Lappano et al. 2012) . The homology structure of the GPER was analyzed and verified with Profile-3D and Ramachandran plot following the method as described previously (Yu et al. 2013 ). The resulting model was used as target for molecular docking simulations using CDOCKER module embedded in the Discover Studio 4.0 (Wu et al. 2003) .
Cell culture
The human prostatic stromal cell line, WPMY-1 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). WPMY-1 cells were routinely cultured in DMEM supplemented with 10% fetal bovine serum, 10 mmol/L HEPES, 1% penicillin, and streptomycin (GIBCO BRL). The cells were maintained at 37 ℃ in a 5% CO2 humidified incubator. ENL was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mmol/L and stored at -20 ℃. Serial dilutions of ENL were made from stock solutions with cell culture medium. DMSO was used as negative control.
Cell proliferation assay
Cell proliferation was determined using the MTT assay. For the MTT assay,
5×10
3 cells/well were cultured in 96-well plates and incubated in standard culture D r a f t medium overnight. In 24 h, the old medium was replaced with fresh medium containing ENL. After incubation for 24 h, the MTT assay was performed as previously described (Chen et al. 2007) . Data are presented from 3 separate experiments and the percentage of ENL-induced cell growth inhibition was determined using DMSO-treated cells (control) as the denominator.
Cell cycle analysis
Propidium iodide staining was performed by flow cytometry to analyze the cell cycle of WPMY-1 cells arrested by ENL. The cells at 40-50% confluence were allowed to grow in the standard culture medium overnight and then transferred to serum-free medium. In 24 h, the old medium was replaced with fresh medium containing ENL.
After incubation for 24 h, the cells were collected and prepared for flow cytometric analysis as described previously (Chen et al. 2007 ). The cell cycle distribution was analyzed using the ModFit LT for Mac V1.01 software.
RNA extraction and real-time PCR
Total RNA was isolated from cells using TRIzol (Invitrogen, La Jolla, CA, USA) according to the manufacturer's protocol. Reverse transcription was used the RT2
First Strand Kit and MMLV-RT (Takara, Dalian, China). The cDNA was subjected to real-time PCR amplification using gene specific primers and 2× Brilliant II SYBR Green QPCR Master Mix (Invitrogen) as described previously (Zhao et al. 2012) . 
Immunoblotting
Proteins extraction and immunoblotting were performed as described previously (Chen et al. 2007) The protein concentration was determined using the Brandford assay (Sigma). About 60 µg of protein extracts were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were incubated with target antibodies. 
Induction of BPH and treatments
BPH induction and treatment were performed as follows. Briefly, 32 male Wistar rats were randomly divided into 4 groups (8 rats per group): (1) untreated control; (2) subcutaneous injection with TP (2mg/rat/d) to induce prostate enlargement; (3) TP-treated group intragastrical administrated with SDG (5mg/rat/d); and (4) TP-treated group intragastrical administrated with Finasteride (a positive control for experimental drugs in BPH studies, 0.1 mg/rat/d). The dose of TP was determined according to other report (Bisson et al. 2014; Wang et al. 2015 
Histological and immunohistochemical studies
Tissues were post-fixed in 4% paraformaldehyde overnight and were cut in a cryostat at 14 µm. One section was stained with Haematoxylin and eosin (H&E) for histological examination, and other sections were processed for immunofluorescence (IF) staining.
For H&E staining, the sections were stained with Harris-modified hematoxylin solution for 8 min, then rinsed with tap water for 10 min. Next, the sections were put in 1% hydrochloric acid-alcohol solution for 30 sec followed by washing with distilled water for 1 min. Subsequently, sections were put in 0.2% ammonia water for 30-60 sec, and then the sections were washed again with distilled water for 5 min. for 10 minutes. After mounting, the stained sections were observed using fluorescence microscope (Carl Zeiss, Jena, Germany).
Statistical Analysis
One-way ANOVA was used to test statistical differences among treatment groups followed by Tukey's multiple comparisons. All experiments in the present study were done at least thrice, and the results were expressed as the mean ± SE and considered significant when P < 0.05.
D r a f t
Results
ENL may bind to GPER
Based on chemical structure similarity between G1 and ENL ( Figure in the G0/G1 phase (59.7%; Figure 3B ; P <0.05), when comparing with control (50.8%). Similarly, The GPER agonist G1 also blocked in cell cycle in the G0/G1 phase (63.9%; Figure 3B ; P <0.05). The sub-G0/G1 (apoptotic cells) contents were not detectable even after an extended treatment time (72 h) and the cells were still blocked in the G0/G1 phase (data not shown).
Furthermore, we detected that both G1 and ENL treatment affected the expression of proteins involved in the cell cycle regulation. As shown in Figure 4 , WPMY-1 cells treated with ENL or G1 showed a reduced cyclin D1 expression concomitantly with p53 and p21 upregulation. It has been demonstrated ERK is one of the important downstream target of GPER (Meyer et al. 2014) . We found that treatment with ENL showed a marked increase of ERK1/2 phosphorylation after treatment for 24 h ( Figure   4 ).
To further demonstrate the requirement of GPER in the inhibitory effect of ENL on cell proliferation, we knocked down GPER expression by siRNA against GPER and performed cell proliferation examination. We found that the cell proliferation rate increased from 58.2% (ENL group) to 82.3% (ENL plus GPER-siRNA). It suggested that the reduction in GPER expression was able to impair partially the growth inhibitory effects exerted by ENL( Figure 3C, D) .
SDG inhibited the enlargement of BPH induced by testosterone propionate
As shown in Figure 5A , there were no statistical differences of body weight of rats between the four treatment groups at the end of the study. Rat prostates were harvested from the blank control group, the TP-induced model group ( (Marshall 1995; Tang et al. 2002) . In our study, we examined that ENL or G1, the agonist of GPER activated ERK1/2 lasting for 24 h and significantly inhibited the proliferation of WPMY-1 and induced G0/G1 cell-cycle arrest. Several previous studies also showed that GPER activation was associated with decreased cell proliferation through sustained activation of ERK1/2. 
2007
). In our study, the G0/G1 cell cycle arrest effects of ENL was further confirmed by increased expression of p53, p21 and decreased expression of cyclin D1 by ENL treatment.
Although we demonstrated that ENL may bind and activate the GPER/ERK signaling and further blocked the proliferation of human prostatic stromal cell line, WPMY-1. Our in vivo data again showed that SDG treatment activated the GPER activation and inhibited the enlargement of BPH. However, we can't exclude the possibility that other mechanisms that involved in the anti-BPH effects of ENL and SDG. ERα is highly expressed in the prostate in both epithelial and stromal cells (Royuela et al. 2001) . A recent study has shown that an imbalance of the androgen level and enhanced estrogenic effects were the main cause of BPH (Farnsworth 1999) . It had been demonstrated the ability of purified lignans to compete with estradiol, stimulate sex hormone binding globulin production, and inhibit steroid binding (Thompson 1998 
